Clinically meaningful responses with dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post hoc analyses from a randomized clinical trial

  • Amy Paller (Creator)
  • Ashish Bansal (Creator)
  • Eric L. Simpson (Contributor)
  • Mark Boguniewicz (Creator)
  • Andrew Blauvelt (Creator)
  • E. Siegfried (Creator)
  • Emma Guttman-Yassky (Creator)
  • T. Hultsch (Creator)
  • Zhen Chen (Creator)
  • Paola Mina-Osorio (Creator)
  • Y. Lu (Creator)
  • Ana Beatris Rossi (Creator)
  • Xinyi He (Creator)
  • Mohamed Kamal (Creator)
  • N. M.H. Graham (Creator)
  • G. Pirozzi (Creator)
  • Marcella Ruddy (Creator)
  • L. Eckert (Creator)
  • A. Gadkari (Creator)

Dataset

Description

This Figshare page contains a video abstract and summary slide. Disclosures Funding Open access was funded by Sanofi and Regeneron Pharmaceuticals, Inc. The current research was sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT03054428. The study sponsors participated in the study design; collection, analysis, and interpretation of the data; writing of the report; and the decision to submit the article for publication. Medical writing/editorial assistance was provided by Carolyn Ellenberger, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. Potential Conflicts of Interest Amy S. Paller has served as an investigator and/or consultant for AbbVie, Amgen, AnaptysBio, Asana, Dermavant, Dermira, Eli Lilly, Galderma, Forte, Incyte, Janssen, LEO Pharma, Matrisys Bioscience, Menlo Therapeutics, MorphoSys/Galapagos, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi. Ashish Bansal, Zhen Chen, Paola Mina-Osorio, Yufang Lu, Xinyi He, Mohamed Kamal, Neil M. H. Graham, Marcella Ruddy, and Abhijit Gadkari are employees and shareholders of Regeneron Pharmaceuticals, Inc. Eric L. Simpson served as an investigator and/or consultant for AbbVie, Boehringer Ingelheim, Dermavant, Eli Lilly, Galderma, Forte, Incyte, Kyowa Hakko Kirin, LEO Pharma, Merck, Menlo Therapeutics, Pfizer, Pierre Fabre Dermo Cosmetique, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, and Valeant. Mark Boguniewicz served as an investigator and/or consultant for Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. Andrew Blauvelt served as a consultant and investigator for AbbVie, Aclaris, Akros, Allergan, Almirall, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, Genentech/Roche, GlaxoSmithKline, Janssen, LEO Pharma, Meiji, Merck Sharp & Dohme, Novartis, Pfizer, Purdue Pharma, Regeneron Pharmaceuticals, Inc., Revance, Sandoz, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, UCB Pharma, Valeant, and Vidac and served as a speaker for Janssen, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme. Elaine C. Siegfried served as a principal investigator for AbbVie, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, LEO Pharma, Novan, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, and UCB and as an investigator for Allergan, Eli Lilly, Janssen, Mayne, Regeneron Pharmaceuticals, Inc., and Verrica. Emma Guttman-Yassky served as an investigator for AbbVie, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, LEO Pharma, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi; as a consultant for AbbVie, Anacor, Asana Biosciences, Daiichi Sankyo, DBV Technologies, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Kyowa, LEO Pharma, Menlo Therapeutics, Novartis, Pfizer, Realm, Regeneron Pharmaceuticals, Inc., and Sanofi and received research support from AbbVie, Celgene, Dermira, Galderma, Innovaderm, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi. Thomas Hultsch, Ana B. Rossi, Gianluca Pirozzi, and Laurent Eckert are employees of Sanofi, and own Sanofi stock/stock options. Ethics approval LIBERTY AD ADOL was conducted in accordance with the ethical standards of the responsible committees and the Declaration of Helsinki and with the International Conference on Harmonization guidelines for Good Clinical Practice. The trial was overseen by an independent data and safety monitoring board. Consent to participate Written informed consent was obtained from all patients or their proxies. © The Author(s) 2019
Date made available2019
PublisherAdis Journals

Cite this